6th International Conference on Early Toxicity Screening (ETS-2006)

Venue: The Edgewater Hotel

Location: Seattle, Washington, United States

Event Date/Time: Jun 22, 2006 End Date/Time: Jun 23, 2006
Registration Date: Jun 22, 2006
Early Registration Date: Apr 03, 2006
Report as Spam

Description

Session 1: Early Prediction of Organ-Specific Toxicity
Chair: Claudia McGinnis

The Use of Primary Human Cells in Early Toxicology Screening for Prediction of Livertoxicity and Hematopoietic Liabilities (Claudia McGinnis, Maria Eckert, Novartis Institutes for Biomedical Research; Cambridge MA)

In Silico Models for the Prediction of Dose Dependent Human Hepatotoxicity (Ailan Cheng, CZ Technologies, LLC. State College, PA)

A Microarray-based Approach to Understanding Drug Bioactivation in Rodent Liver (Greg Slatter and Wei Tang, Rosetta Inpharmatics LLC (A subsidiary of Merck & Co., Inc.) Seattle, WA, and Drug Metabolism Research, Merck Research Laboratories, Rahway NJ)

QT Prolongation: A Roche Perspective on Predictive Assays (Heather Guthrie, Hoffmann-La Roche Inc.; Nutley, NJ)

New Cell Models & Assays in Cardiac Safety Profiling (Thomas Meyer, Multi Channel Systems MCS GmbH; Sartipy, Peter Cellartis SA; Guenther, Elke Natural and Medical Sciences Institute at the Tuebingen University)

Predictive In Vitro Hemotoxicology and the Concept of In Vitro Comparative Toxicity, Cross-Platform Technology (Ivan N. Rich, HemoGenix, Inc.; Colorado Springs, CO)

Medium Throughput Automated In Vitro and Ex Vivo Assays for Frontloading Bone Marrow Toxicity Screening (Fran├žois Pognan AstraZeneca, Global Safety Assessment, Cheshire UK)

Skeletal Muscle: A Target for Toxicity by Marketed and Investigational Drugs (Russell Westwood, AstraZeneca R&D Alderley Park; Cheshire, UK)

Session II:
Novel Technologies for Early Toxicity Screening
Chair: Albert P. Li

Microfluidic (Lab-on-a-chip) Screening Technologies (Albert Folch, University of Washington, Seattle, WA)

Integrated Discrete Co-culture Technologies (Organ(s)-on-a-Chip) for Toxicity Screening (Albert P. Li, The ADMET Group LLC; Rockville, MD)

Development of an Early Toxicity Screening Cascade for the Assessment of the Activity of Antibody-Drug Conjugates (May Sutherland, Changpu Yu, Renee McCormick, Kerry Klussman, Julie McEarchern, Che Law, and Alan Wahl. Seattle Genetics, Inc., Seattle, WA)

Histologically Defined Biomarkers in Drug Development (Martin Shaw, Biotrin International; Dublin, IRELAND)
Friday, June 23, 2006

Session 3:
Application of Cell-lines in Toxicity Screening
Chair: Jim McKim

Improving Drug Candidate Selection by Incorporating In Vitro Toxicity Data into the Discovery Process (Jim McKim, CeeTox, Inc.; Kalamazoo, MI)

Comparison of In Vitro Assays of Cellular Toxicity in the Human Hepatic Cell Line HepG2 (Silvia Miret, Unilever R&D; Vlaardingen, The NETHERLANDS)

Validation & Regulatory Acceptance of In Vitro Toxicity/Potency Assays (John W. Harbell, Institute for In Vitro Sciences, Inc.; Gaithersburg, MD)

Session 4:
General Early Toxicity Screening Approaches
Chair: Weichao Chen

Bioluminescent Approaches For In Vitro ADME/Tox
(James J. Cali, Promega Corp.; Madison, WI)

The Role of Early In Vivo Toxicity Screening in Drug Safety Evaluation (Jessica E. Sutherland, Charles River Laboratories Preclinical Services; Worcester, MA)

Managing Oxidative Bioactivation in Drug Discovery (Wei Tang, Merck Research Laboratories, Rahway, NJ)

Detection and Quantification of Neurotoxic A42 Aggregates (Mary Michael Brodey, BioSource Cytokines & Signaling; Invitrogen Corporation Camarillo, CA)

Strategies to Eliminate Toxicity with Structural Modification Approaches in Drug Discovery (Weichao Chen, Arena Pharmaceuticals, San Diego, CA

A New Approach to Toxicity Testing at the NTP: High Throughput Screening (Kristine L. Witt, NIEHS; Research Triangle Park, NC)

Venue

2411 Alaskan Way, Pier 67
Seattle
Washington
United States
MORE INFO ON THIS VENUE

Additional Information

Early Registration Discounts and Multiple Event Discounts http://www.isciencex.com/register.htm

Types